Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Pharmacokinetic and Tolerability Study of Amcenestrant Given as a Single Dose in Female Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function

NCT05126329 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05126329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Pharmacokinetic and Tolerability Study of Amcenestrant Given as a Single Dose in Female Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Terminated
Start date
November 15, 2021
Completion date
May 16, 2022
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic function abnormal